Poster Session : PS 1448 ; Hemato-Oncology(Oncology) : The Results of Weekly Docetaxel Chemotherapy in Pretreated Patients with Advenced Gastric Cancer = Poster Session : PS 1448 ; Hemato-Oncology(Oncology) : The Results of Weekly Docetaxel Chemotherapy in Pretreated Patients with Advenced Gastric Cancer

다국어 초록 (Multilingual Abstract)

Background: Docetaxel has proven its efficacy in the treatment of advanced gastric cancer. Weekly chemotherapy is well-tolerated in patients with poor performance status (PS). Therefore, we analyzed the results of weekly docetaxel mono chemotherapy after progression with previous treatment in advanced gastric cancer patients with poor PS. Methods: We performed a retrospective analysis involving 32 patients with advanced gastric cancer who had weekly docetaxel treatment as above 2nd line chemotherapy. Results: Patients with PS more than ECOG 2 were about 90% (29/32). The median survival of patients who were treated by weekly docetaxel as 2nd line therapy was 209 days (95% CI 178-240 days). There was no complete and partial response. The disease control rate including stable disease was 34.4% (11/32). Median survival for all patients was 114 days (95% CI 71-156 days). Patients who were treated by weekly docetaxel as 2nd or 3rd line chemotherapy had a median survival time of 189 days (95% CI, 151-227 days) which was significantly longer than that were treated as above 4th line chemotherapy (median 189 days vs. 98 days; P<0.01, log-rank test). Seven patients took 4-week schedule (4-wk), 25 patients received modified 3-week treatment (3-wk) of docetaxel due to toxicity. In subgroup analysis, there was a tendency of longer progression free survival (PFS) in patients with 3-wk than 4-wk (PFS:75 days in 3-wk vs. 47 days in 4-wk, P=0.06). As 2nd line chemotherapy, 3-wk showed signifi-cant longer PFS than 4-wk in weekly docetaxel chemotherapy (p=0.037). Toxicity was tolerable. Conclusions: Weekly docetaxel chemotherapy as 2nd line treatment showed overall survival which is comparable to other 2nd line chemotherapy in patients with advanced gastric cancer. Modified 3-week treatment might be better than 4-week docetaxel schedule as 2nd line chemotherapy in patients with poor PS.